BEST of ASCO Portugal 2024 - Early Breast Cancer
Resumo
Na Conferência ASCO de 2024, foram apresentados vários trabalhos inovadores na área do Cancro da Mama Precoce, que se aprofundam em biomarcadores antigos e novos e no seu potencial para informar potenciais decisões de mudança de práticas. Esta revisão destaca quatro das apresentações mais relevantes neste cenário de doença.
Downloads
Referências
Cortazar P, Zhang L, Untch M, Mehta K, Costantino JP, Wolmark N, et al. Pathological complete response and long-term clinical benefit in breast cancer: The CTNeoBC pooled analysis. Lancet. 2014;384(9938):164–72.
Hamy AS, Darrigues L, Laas E, De Croze D, Topciu L, Lam GT, et al. Prognostic value of the residual cancer burden index according to breast cancer subtype: Validation on a cohort of bc patients treated by neoadjuvant chemotherapy. PLoS One. 2020;15(6 June):1–17.
Schmid P, Cortes J, Pusztai L, McArthur H, Kümmel S, Bergh J, et al. Pembrolizumab for Early Triple-Negative Breast Cancer. N Engl J Med. 2020 Feb;382(9):810–21.
Davies C, Godwin J, Gray R, Clarke M, Cutter D, Darby S, et al. Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials. Lancet (London, England). 2011 Aug;378(9793):771–84.
Cherny NI, Dafni U, Bogaerts J, Latino NJ, Pentheroudakis G, Douillard J-Y, et al. ESMO-Magnitude of Clinical Benefit Scale version 1.1. Ann Oncol Off J Eur Soc Med Oncol. 2017 Oct;28(10):2340–66.
